Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Drug developers Retension Pharmaceuticals and TRex Bio filed paperwork for U.S. initial public offerings on Friday. The filings reinforce the biotech pipeline for the fall IPO window, according to Reuters.
Why it matters — A TREX watcher would care because TRex Bio's IPO filing signals momentum in the biotech IPO pipeline that may be relevant to the broader sector landscape around the company.